Pharmabiz29m
Caris Life Sciences collaborates with Ontada to advance oncology research and the adoption of precision medicine
Caris Life Sciences collaborates with Ontada to advance oncology research and the adoption of precision medicine: Irving, Texas Saturday, January 18, 2025, 15:00 Hrs [IST] Caris L ...
Pharmabiz1h
UAE health ministry approves Biomerica’s Fortel PSA Screening Test to detect an early sign of prostate cancer
UAE health ministry approves Biomerica’s Fortel PSA Screening Test to detect an early sign of prostate cancer: Irvine, California Saturday, January 18, 2025, 14:00 Hrs [IST] Bio ...
Pharmabiz2h
In 2024 EMA recommends 114 medicines for marketing authorisation; 46 had a new active substance
EMA recommends 114 medicines for marketing authorisation; 46 had a new active substance: Amsterdam, The Netherlands Saturday, January 18, 2025, 13:00 Hrs [IST] European Me ...
Pharmabiz1h
Avicanna enters scientific and medical affairs collaboration with Vectura Fertin Pharma
Avicanna enters scientific and medical affairs collaboration with Vectura Fertin Pharma: Toronto Saturday, January 18, 2025, 13:30 Hrs [IST] Avicanna Inc., a commercial stage, int ...
Pharmabiz3h
WHO launches US$ 1.5 billion Health Emergency Appeal to tackle unprecedented global health crises
WHO launches US$ 1.5 billion Health Emergency Appeal to tackle unprecedented global health crises: Geneva Saturday, January 18, 2025, 12:00 Hrs [IST] Conflict, climate change, epi ...
Pharmabiz4h
Boehringer Ingelheim’s phase III CONNEX clinical programme of iclepertin in schizophrenia fails to meet primary and key secondary endpoints
Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...
Pharmabiz1d
ACT commits Rs. 8.33 crore to the future of rural healthcare in India with Khushi Baby & Medoplus
ACT, an Indian venture philanthropy platform, has committed Rs. 8.33 crore in catalytic grants to Khushi Baby and Medoplus; social startups that are pioneering tech-first solutions to revolutionise ...
Pharmabiz1d
Glaukos announces positive clinical updates for its iDose sustained-release procedural pharmaceutical platform
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced several ...
Pharmabiz1d
Vistagen reports positive results from exploratory phase 2A study of PH284 in cancer cachexia
Vistagen, a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, announced positive results from an exploratory phase 2A study of PH284 in cancer ...
Pharmabiz1d
Signet begins patient dosing in phase I trial in China for SIGX1094 to treat diffuse gastric cancer and other advanced solid tumours
Signet Therapeutics (Signet), a clinical-stage biotech company leveraging organoids and AI to develop first-in-class cancer therapies, announced that the first patient has been dosed in the phase I ...
Pharmabiz1d
Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome
Acadia Pharmaceuticals Inc., a company is advancing breakthroughs in neuroscience to elevate life, announced that the company has submitted a Marketing Authorization Application (MAA) to the European ...
Pharmabiz1d
Olfactive Biosolutions granted third dual GLP-1/GIP patent in US to repurpose food molecules for weight management and blood sugar regulation
Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in US patent US 12,171,727 B1 ...